- Home
- ROIV vs GKOS Comparison
ROIV vs GKOS Comparison
Compare ROIV & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- GKOS
- Stock Information
- Founded
- ROIV 2014
- GKOS 1998
- Country
- ROIV United Kingdom
- GKOS United States
- Employees
- ROIV N/A
- GKOS N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- GKOS Medical/Dental Instruments
- Sector
- ROIV Health Care
- GKOS Health Care
- Exchange
- ROIV Nasdaq
- GKOS Nasdaq
- Market Cap
- ROIV 8.4B
- GKOS 8.4B
- IPO Year
- ROIV N/A
- GKOS 2015
- Fundamental
- Price
- ROIV $11.27
- GKOS $159.45
- Analyst Decision
- ROIV Strong Buy
- GKOS Strong Buy
- Analyst Count
- ROIV 8
- GKOS 13
- Target Price
- ROIV $17.93
- GKOS $147.23
- AVG Volume (30 Days)
- ROIV 5.1M
- GKOS 662.3K
- Earning Date
- ROIV 02-11-2025
- GKOS 02-19-2025
- Dividend Yield
- ROIV N/A
- GKOS N/A
- EPS Growth
- ROIV N/A
- GKOS N/A
- EPS
- ROIV 5.89
- GKOS N/A
- Revenue
- ROIV $129,128,999.00
- GKOS $360,347,000.00
- Revenue This Year
- ROIV $15.98
- GKOS $22.69
- Revenue Next Year
- ROIV N/A
- GKOS $26.76
- P/E Ratio
- ROIV $1.91
- GKOS N/A
- Revenue Growth
- ROIV 145.68
- GKOS 18.70
- 52 Week Low
- ROIV $9.69
- GKOS $83.90
- 52 Week High
- ROIV $13.06
- GKOS $161.31
- Technical
- Relative Strength Index (RSI)
- ROIV 46.46
- GKOS 63.50
- Support Level
- ROIV $10.89
- GKOS $142.71
- Resistance Level
- ROIV $11.26
- GKOS $158.01
- Average True Range (ATR)
- ROIV 0.36
- GKOS 4.93
- MACD
- ROIV -0.02
- GKOS 0.11
- Stochastic Oscillator
- ROIV 47.75
- GKOS 90.02
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.